CLPT

+ Watchlist + Portfolio

ClearPoint Neuro Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.96
52-Week Range: $8.27 – $30.10
Market Cap: $463.36M
P/E (TTM): —
EPS (TTM): -1.12
Dividend Yield: —

Advanced Metrics

Price/Book: 43.03
PEG Ratio: 0.61
Return on Equity: -226.52%
Return on Assets: -24.43%
Gross Margin: 62.61%
Operating Margin: -94.15%
Profit Margin: -81.76%
Current Ratio: 4.75
Debt/Equity: 5.93
Total Debt: $63.95M
Free Cash Flow: $-14.05M
Revenue Growth: 18.10%
Earnings Growth: —
Enterprise Value: $497.94M

CLPT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$20.55M	$23.95M	$31.39M	$36.97M
Cost of Revenue	$7.02M	$10.34M	$12.27M	$14.28M
Gross Profit	$13.53M	$13.61M	$19.12M	$22.69M
Research & Development	$10.89M	$11.71M	$12.39M	$13.90M
Selling, General & Admin	$18.97M	$24.35M	$26.46M	$32.96M
Operating Expenses	$29.86M	$36.06M	$38.86M	$46.86M
Operating Income	-$16.33M	-$22.45M	-$19.73M	-$24.16M
EBITDA	-$15.58M	-$20.99M	-$16.48M	-$20.86M
Pretax Income	-$16.43M	-$22.09M	-$18.90M	-$25.48M
Income Tax	—	—	$12.00K	$55.00K
Net Income	-$16.43M	-$22.09M	-$18.91M	-$25.54M
Diluted EPS	-0.68	-0.90	-0.70	-0.90
Diluted Shares	24.18M	24.61M	27.03M	28.32M

CLPT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$27.61M	$23.14M	$20.10M	$45.92M
Receivables	$2.67M	$3.21M	$4.71M	$6.55M
Inventory	$9.30M	$7.91M	$6.86M	$8.36M
Current Assets	$51.18M	$36.17M	$33.36M	$63.60M
Total Assets	$55.49M	$42.66M	$39.19M	$97.75M
Current Liabilities	$6.79M	$7.43M	$10.35M	$10.77M
Long-Term Debt	$9.89M	$9.95M	—	$49.08M
Total Debt	$11.99M	$13.94M	$3.57M	$58.23M
Total Liabilities	$18.60M	$21.49M	$13.80M	$69.73M
Retained Earnings	-$150.37M	-$172.46M	-$191.37M	-$216.91M
Shareholders' Equity	$36.89M	$21.17M	$25.39M	$28.02M
Working Capital	$44.39M	$28.74M	$23.01M	$52.84M
Net Debt	—	—	—	$3.15M

CLPT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$16.17M	-$13.72M	-$8.95M	-$23.93M
Capital Expenditure	-$1.15M	-$1.05M	-$275.00K	-$522.00K
Free Cash Flow	-$17.31M	-$14.77M	-$9.22M	-$24.45M
Depreciation & Amortisation	$777.00K	$1.46M	$1.90M	$2.24M
Stock-Based Compensation	$4.13M	$6.08M	$6.91M	$8.18M
Investing Cash Flow	-$10.74M	$8.95M	-$275.00K	$615.00K
Financing Cash Flow	$409.00K	$296.00K	$6.19M	$50.18M
Net Change in Cash	-$26.49M	-$4.47M	-$3.04M	$26.87M

CLPT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$8.48M	$9.21M	$8.86M	$10.41M	$12.13M
Cost of Revenue	$3.35M	$3.66M	$3.26M	$4.01M	$4.37M
Gross Profit	$5.13M	$5.56M	$5.60M	$6.40M	$7.76M
Research & Development	$3.38M	$3.83M	$3.45M	$3.24M	$4.52M
Selling, General & Admin	$7.92M	$7.41M	$7.42M	$10.21M	$11.71M
Operating Expenses	$11.29M	$11.24M	$10.88M	$13.45M	$16.23M
Operating Income	-$6.16M	-$5.68M	-$5.28M	-$7.04M	-$8.48M
EBITDA	-$5.67M	-$5.11M	-$4.91M	-$5.01M	-$7.05M
Pretax Income	-$6.01M	-$5.81M	-$5.88M	-$7.78M	-$9.54M
Income Tax	$18.00K	$25.00K	$8.00K	$4.00K	$8.00K
Net Income	-$6.03M	-$5.84M	-$5.89M	-$7.79M	-$9.55M
Diluted EPS	-0.22	-0.21	-0.21	—	-0.32
Diluted Shares	27.72M	28.26M	28.43M	—	29.55M

CLPT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$12.39M	$41.54M	$38.22M	$45.92M	$35.59M
Receivables	$3.65M	$4.26M	$4.00M	$6.55M	$8.66M
Inventory	$6.58M	$6.29M	$6.58M	$8.36M	$8.57M
Current Assets	$24.21M	$53.99M	$51.33M	$63.60M	$54.88M
Total Assets	$30.07M	$62.87M	$60.36M	$97.75M	$93.42M
Current Liabilities	$6.87M	$7.40M	$8.05M	$10.77M	$9.48M
Long-Term Debt	—	$28.84M	$29.20M	$49.08M	$49.64M
Total Debt	$3.44M	$35.46M	$35.74M	$58.23M	$63.59M
Total Liabilities	$10.08M	$43.13M	$44.48M	$69.73M	$74.58M
Retained Earnings	-$197.40M	-$203.23M	-$209.12M	-$216.91M	-$226.46M
Shareholders' Equity	$19.99M	$19.74M	$15.87M	$28.02M	$18.84M
Working Capital	$17.35M	$46.59M	$43.28M	$52.84M	$45.40M
Net Debt	—	—	—	$3.15M	$14.05M

CLPT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.17M	-$2.55M	-$3.12M	-$12.08M	-$7.97M
Capital Expenditure	-$183.00K	-$91.00K	-$199.00K	-$49.00K	-$645.00K
Free Cash Flow	-$6.36M	-$2.64M	-$3.32M	-$12.13M	-$8.61M
Depreciation & Amortisation	$334.00K	$626.00K	$426.00K	$851.00K	$1.11M
Stock-Based Compensation	$1.91M	$2.27M	$2.02M	$1.98M	$2.22M
Investing Cash Flow	-$183.00K	-$91.00K	-$199.00K	$1.09M	-$645.00K
Financing Cash Flow	-$1.36M	$31.98M	$0.00	$19.56M	-$1.84M
Net Change in Cash	-$7.72M	$29.33M	-$3.32M	$8.57M	-$10.46M

Market Snapshot

About

ClearPoint Neuro Inc. develops and commercializes platforms for image-guided minimally invasive neurosurgery. Based in Solana Beach, California, the company's ClearPoint system enables neurosurgeons to perform precise interventions inside the brain using real-time MRI guidance. Applications include deep brain stimulation for movement disorders, laser ablation for epilepsy and tumors, and delivery of biologics for neurological conditions. ClearPoint generates revenue from capital equipment sales, disposable navigation products, and case support services, serving medical centers performing advanced functional and therapeutic neurosurgery procedures.